The Department of Health and Human Services Oct. 2 released final guidance detailing the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program. It also explains how the Centers for Medicare & Medicaid Services will help ensure Medicare beneficiaries can access drugs at the negotiated prices from the first and second cycles when those prices become effective in 2026 and 2027, respectively. CMS in August announced lower prices for 10 drugs covered by Part D that were selected in the first round. AHA in July commented on the guidance for the program, expressing concern about CMS’ proposal to retrospectively effectuate access to the negotiated prices and its implications for the 340B program. AHA will share more information soon about specific implications of the final guidance for hospitals. 

Related News Articles

Headline
The AHA today voiced support for the Rural Hospital Support Act (S. 335), legislation that would make the Medicare-dependent Hospital program and low-volume…
Headline
The AHA Jan. 31 commended Sens. Bill Cassidy, R-La., Catherine Cortez Masto, D-Nev., John Cornyn, R-Texas., and Michael Bennet, D-Colo., on draft legislation…
Headline
The White House Office of Management and Budget Jan. 29 rescinded a memo it issued two days earlier directing federal agencies to temporarily pause federal…
Headline
An analysis by KFF released Jan. 28 found that Medicare Advantage insurers made nearly 50 million prior authorization determinations in 2023. The finding…
Headline
The White House Office of Management and Budget late Jan. 27 issued a memo directing federal agencies to temporarily pause federal grants, loans and other…
Headline
The AHA Jan. 27 voiced support for the Centers for Medicare & Medicaid Services proposed rule on policy and technical changes to Medicare Advantage and…